Understand the source comparison
How to Use Peptides for IBD: Comparison by Mechanism
BPC-157 Promotes angiogenesis, upregulates VEGF and bFGF, accelerates mucosal healing 250–500mcg daily Once daily ~4 hours (requires daily dosing) Most evidence for direct GI tissue repair; studied extensively in colitis models Thymosin Beta-4 Enhances T-regul
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Promotes angiogenesis, upregulates VEGF and bFGF, accelerates mucosal healing
- 250–500mcg daily
- Once daily
- ~4 hours (requires daily dosing)
- Most evidence for direct GI tissue repair; studied extensively in colitis models
- Thymosin Beta-4
- Enhances T-regulatory cell function, reduces TNF-alpha, supports epithelial barrier integrity
- 5–10mg
- Twice weekly
- 3–4 days
- Immune modulation focus; complements rather than replaces biologics
- KPV
- Inhibits NFκB pathway, reduces IL-6 and IL-1beta, anti-inflammatory at transcription level
- 200–500mcg daily (subQ) or 500mcg–2mg (oral)
- 2–3 hours
- Potent anti-inflammatory; oral bioavailability questionable, subQ preferred
- Thymalin
- Thymus-derived peptide, normalises T-cell ratios, restores immune tolerance
- 2–3 times weekly
- 24–48 hours
- Broad immune regulation; limited IBD-specific data compared to BPC-157